CoChat

Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

Open access
Page, David B., Yuan, Jianda, Redmond, David, Wen, Y Hanna, Durack, Jeremy C., Emerson, Ryan, Solomon, Stephen, Dong, Zhiwan, Wong, Phillip, Comstock, Christopher, Diab, Adi, Sung, Janice, Maybody, Majid, Morris, Elizabeth, Brogi, Edi, Morrow, Monica, Sacchini, Virgilio, Elemento, Olivier, Robins, Harlan, Patil, Sujata, Allison, James P., Wolchok, Jedd D., Hudis, Clifford, Norton, Larry, McArthur, Heather L. · 2016 · Cancer Immunology Research
Cited by 170

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

In early-stage breast cancer, the degree of tumor-infiltrating lymphocytes (TIL) predicts response to chemotherapy and overall survival. Combination immunotherapy with immune checkpoint antibody plus tumor cryoablation can induce lymphocytic infiltrates and improve survival in mice. We used T-cell receptor (TCR) DNA sequencing to evaluate both the effect of cryoimmunotherapy in humans and the feasibility of TCR sequencing in early-stage breast cancer. In a pilot clinical trial, 18 women with early-stage breast cancer were treated preoperatively with cryoablation, single-dose anti–CTLA-4 (ipilimumab), or cryoablation + ipilimumab. TCRs within serially collected peripheral blood and tumor tissue were sequenced. In baseline tumor tissues, T-cell density as measured by TCR sequencing correlated with TIL scores obtained by hematoxylin and eosin (H&E) staining. However, tumors with little or no lymphocytes by H&E contained up to 3.6 × 106 TCR DNA sequences, highlighting the sensitivity of the ImmunoSEQ platform. In this dataset, ipilimumab increased intratumoral T-cell density over time, whereas cryoablation ± ipilimumab diversified and remodeled the intratumoral T-cell clonal repertoire. Compared with monotherapy, cryoablation plus ipilimumab was associated with numerically greater numbers of peripheral blood and intratumoral T-cell clones expanding robustly following therapy. In conclusion, TCR sequencing correlates with H&E lymphocyte scoring and provides additional information on clonal diversity. These findings support further study of the use of TCR sequencing as a biomarker for T-cell responses to therapy and for the study of cryoimmunotherapy in early-stage breast cancer. Cancer Immunol Res; 4(10); 835–44. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0013

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 170

Metadata

Authors
Page, D. B., Yuan, J., Redmond, D., Wen, Y. H., Durack, J. C., Emerson, R., Solomon, S., Dong, Z., Wong, P., Comstock, C., Diab, A., Sung, J., Maybody, M., Morris, E., Brogi, E., Morrow, M., Sacchini, V., Elemento, O., Robins, H., Patil, S., Allison, J. P., Wolchok, J. D., Hudis, C., Norton, L., & McArthur, H. L.
Venue
Cancer Immunology Research
Published
2016-10-01
Volume
4
Issue
10
Pages
835-844
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2517192251
Cited by
170
References
8
FWCI
7.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. https://app.cochat.ai/papers/10.1158/2326-6066.cir-16-0013
The paper
Page, D. B., Yuan, J., Redmond, D., Wen, Y. H., Durack, J. C., Emerson, R., Solomon, S., Dong, Z., Wong, P., Comstock, C., Diab, A., Sung, J., Maybody, M., Morris, E., Brogi, E., Morrow, M., Sacchini, V., Elemento, O., Robins, H., . . . McArthur, H. L. (2016). Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-16-0013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.